(19)
(11) EP 4 815 918 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24898922.0

(22) Date of filing: 02.12.2024
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 38/06(2006.01)
A61K 38/44(2006.01)
A61K 47/38(2006.01)
A61P 25/28(2006.01)
 A61K 31/198(2006.01)
A61K 31/122(2006.01)
A61K 47/36(2006.01)
A61K 47/42(2017.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/36; A61K 47/38; A61P 25/28; A61K 31/198; A61K 31/122; A61K 9/006; A61K 47/26; A61K 38/446; A61K 38/063; C12Y 115/01001
(86) International application number:
PCT/US2024/058158
(87) International publication number:
WO 2025/117984 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 30.11.2023 US 202363604873 P

(71) Applicant: Beyond Barriers Therapeutics, Inc.
Glencoe, IL 60022 (US)

(72) Inventors:
  • KOLE, Ryan
    Glencoe, IL 60022 (US)
  • MARSHALL, John
    Glencoe, IL 60022 (US)
  • POLSKY, Charles
    Glencoe, IL 60022 (US)
  • REINHARDT, Brian
    Glencoe, IL 60022 (US)
  • DEGREGORIS, Thomas A.
    Glencoe, IL 60022 (US)

(74) Representative: Schnappauf, Georg 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)

   


(54) SUBLINGUAL OR BUCCAL DOSAGE FORMS COMPRISING ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS